Frontiers in Medicine (Oct 2022)

A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis — A phase I clinical trial

  • Stephan Thurau,
  • Christoph M. E. Deuter,
  • Arnd Heiligenhaus,
  • Uwe Pleyer,
  • Joachim Van Calster,
  • Talin Barisani-Asenbauer,
  • Franz Obermayr,
  • Franz Obermayr,
  • Stefan Sperl,
  • Romana Seda-Zehetner,
  • Gerhild Wildner

DOI
https://doi.org/10.3389/fmed.2022.1023224
Journal volume & issue
Vol. 9

Abstract

Read online

Uveitis is a T cell-mediated, intraocular inflammatory disease and one of the main causes of blindness in industrialized countries. There is a high unmet need for new immunomodulatory, steroid-sparing therapies, since only ciclosporin A and a single TNF-α-blocker are approved for non-infectious uveitis. A new small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme pivotal for de novo synthesis of pyrimidines, has a high potency for suppressing T and B cells and has already proven highly effective for treating uveitis in experimental rat models. Systemic and intraocular application of KIO-100 (PP-001) (previously called PP-001, now KIO-100) could efficiently suppress rat uveitis in a preventive as well as therapeutic mode. Here we describe the outcome of the first clinical phase 1 trial comparing three different doses of a single intraocular injection of KIO-100 (PP-001) in patients with non-infectious posterior segment uveitis. No toxic side effects on intraocular tissues or other adverse events were observed, while intraocular inflammation decreased, and visual acuity significantly improved. Macular edema, a sight-threatening complication in uveitis, showed regression 2 weeks after intraocular KIO-100 (PP-001) injection in some patients, indicating that this novel small molecule has a high potential as a new intraocular therapy for uveitis.Clinical trial registration[https://www.clinicaltrials.gov/ct2/show/NCT03634475], identifier [NCT03634475].

Keywords